Skip to main content

Table 2 IC50 of a single drug in LAR cell lines

From: Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy

Drugs

MDA-MB-453

CAL-148

Chidamide (μM)

1.09

2.4

Enzalutamide (μM)

18.67

149.3

Paclitaxel (nM)

4.12

3.9

Alpelisib (μM)

0.77

1.09

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us